vorinostat has been researched along with Agnogenic Myeloid Metaplasia in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Because primary myelofibrosis (PMF) originates at the level of the pluripotent hematopoietic stem cell (HSC), we examined the effects of various therapeutic agents on the in vitro and in vivo behavior of PMF CD34(+) cells." | 1.36 | Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. ( Hoffman, R; Li, Y; Lu, M; Najfeld, V; Tripodi, J; Wang, X; Xu, M; Zhang, W, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersen, CL | 1 |
| Mortensen, NB | 1 |
| Klausen, TW | 1 |
| Vestergaard, H | 1 |
| Bjerrum, OW | 1 |
| Hasselbalch, HC | 1 |
| Lee, J | 1 |
| Wang, X | 1 |
| Zhang, W | 1 |
| Tripodi, J | 1 |
| Lu, M | 1 |
| Xu, M | 1 |
| Najfeld, V | 1 |
| Li, Y | 1 |
| Hoffman, R | 1 |
1 trial available for vorinostat and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.
Topics: Humans; Hydroxamic Acids; Polycythemia Vera; Primary Myelofibrosis; Treatment Outcome; Vorinostat | 2014 |
2 other studies available for vorinostat and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Blood Transfusion; Humans; Hyd | 2009 |
Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Bone M | 2010 |